ArticleCardiovascular diabetology2025
Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Statin-Related Myotoxicity: A Narrative Review and Practical Approach for General Internists.Journal of general internal medicine · 2026Review
- Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.Circulation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatins are a cornerstone of cardiovascular disease prevention, but growing evidence suggests they may increase the risk of new-onset type 2 diabetes. The cardiovascular implications of diabetes that develops during statin therapy, however, remain unclear. This study aimed to evaluate whether incident diabetes during statin use is associated with increased risk of major adverse cardiovascular events (MACE) or all-cause mortality, compared with individuals with preexisting diabetes and statin users who remained free of diabetes.
methodsWe conducted two retrospective cohort studies using data from the Korean National Health Insurance Service (KNHIS) database between 2009 and 2020, which includes nationwide, population-based data from both primary and secondary care settings. From a source population of 1,500,959 adults, Study 1 identified 4371 individuals who had used statins continuously for ≥ 730 days before receiving a new diagnosis of type 2 diabetes mellitus (T2DM). These individuals were propensity score-matched 1:1 to individuals who initiated statin therapy after a prior diagnosis of T2DM, matched by age, sex, and low-density lipoprotein cholesterol levels. In Study 2, 4191 statin users who developed T2DM during follow-up were matched 1:1 with statin users who remained diabetes-free during the same period. The primary outcome was MACE, defined as a composite of myocardial infarction and stroke. All-cause mortality was assessed as a secondary outcome.
resultsIn Study 1, individuals who developed diabetes during statin therapy had a significantly lower risk of MACE compared with those who initiated statins after diabetes diagnosis (adjusted hazard ratio [aHR] 0.607; 95% confidence interval [CI], 0.458-0.805; p = 0.0005), primarily driven by a reduced stroke risk (aHR 0.504; 95% CI, 0.357-0.711; p < 0.001). In Study 2, incident diabetes during statin use was not associated with increased risk of MACE (aHR 1.122; 95% CI, 0.784-1.605; p = 0.53) or all-cause mortality (aHR 0.555; 95% CI, 0.290-1.063; p = 0.0758), compared with remaining diabetes-free.
conclusionsDiabetes that develops during statin therapy was associated with a lower risk of MACE compared with initiating statins after diabetes diagnosis and was not linked to increased risk of MACE or all-cause mortality compared with remaining diabetes-free.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.